Published in Cancer on November 01, 1978
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma. Thorax (1980) 0.98
A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 7.81
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res (1987) 4.44
Macrophage-lymphocyte interaction in the antigen-induced blastogenic response of human peripheral blood leukocytes. J Immunol (1968) 4.25
The transformation of column-purified lymphocytes with nonspecific and specific antigenic stimuli. J Immunol (1968) 4.24
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 3.86
Impaired in vitro lymphocyte transformation in Hodgkin's disease. N Engl J Med (1965) 3.54
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet (2000) 3.25
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med (1988) 2.93
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis (1985) 2.64
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol (1970) 2.40
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (1991) 2.38
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol (1997) 2.36
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol (1999) 2.29
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Minority cancer patients and their providers: pain management attitudes and practice. Cancer (2000) 2.13
Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol (2008) 2.12
Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol (1995) 2.08
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol (2006) 1.91
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol (1995) 1.85
The natural history of breast cancer patients with brain metastases. Cancer (1979) 1.82
Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res (1986) 1.82
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med (1982) 1.79
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am (1998) 1.77
Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology (1991) 1.67
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1995) 1.67
Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis (1984) 1.67
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med (1994) 1.66
Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res (1979) 1.62
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Early and delayed clinical cardiotoxicity of doxorubicin. Cancer (1985) 1.61
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg (1999) 1.60
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol (1997) 1.58
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol (1998) 1.58
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer (1998) 1.57
Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer (1991) 1.57
Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer (2001) 1.57
Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med (1984) 1.57
Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med (1987) 1.55
Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol (2010) 1.55
Cancer immunotherapy. Can Med Assoc J (1979) 1.54
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol (2007) 1.54
Tamoxifen-induced female androgenetic alopecia in a patient with breast cancer. Ann Intern Med (1997) 1.51
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am (1999) 1.48
Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol (1998) 1.48
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med (1974) 1.48
Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A (1985) 1.47
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol (2000) 1.46
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol (2011) 1.45
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res (1997) 1.43
Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv (1983) 1.43
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol (2011) 1.42
The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg (1989) 1.41
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg (1998) 1.40
Immunomorphological features of prognostic significance in Dukes' Class B colorectal carcinoma. Cancer Res (1977) 1.40
Discouraging news for high-dose chemotherapy in high-risk breast cancer. Lancet (1998) 1.40
The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. J Natl Cancer Inst (1977) 1.40
Cells capable of colony formation in the peripheral blood of man. Science (1971) 1.40
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol (1994) 1.39
GM-CSF, carboplatin, doxorubicin: a phase I study. Cancer Chemother Pharmacol (1994) 1.38
Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med (1971) 1.38
Avicins: triterpenoid saponins from Acacia victoriae (Bentham) induce apoptosis by mitochondrial perturbation. Proc Natl Acad Sci U S A (2001) 1.37
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol (1988) 1.36
Causes of death in breast cancer: a clinicopathologic study. Cancer (1980) 1.34
Antigen dose in the human immune response. Dose-relationships in the human immune response to Keyhole limpet hemocyanin. J Lab Clin Med (1971) 1.32
Clinical course of breast cancer patients with liver metastases. J Clin Oncol (1987) 1.32
Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer (1992) 1.31
Pulmonary complications of acute leukemia. Cancer (1966) 1.30
Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor-kappaB by inhibiting both its nuclear localization and ability to bind DNA. Proc Natl Acad Sci U S A (2001) 1.30
Immunological characterization of homosexual males. Cancer Res (1983) 1.29